Olinvacimab is under investigation in clinical trial NCT03033524 (Trial to Evaluate the Safety of Ttac-0001(tanibirumab) in Recurrent Glioblastoma).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Olinvacimab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Olinvacimab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Olinvacimab. |
| Estrone | Estrone may increase the thrombogenic activities of Olinvacimab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Olinvacimab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Olinvacimab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Olinvacimab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Olinvacimab. |
| Estriol | Estriol may increase the thrombogenic activities of Olinvacimab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Olinvacimab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Olinvacimab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Olinvacimab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Olinvacimab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Olinvacimab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Olinvacimab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Olinvacimab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Olinvacimab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Olinvacimab. |
| Equol | Equol may increase the thrombogenic activities of Olinvacimab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Olinvacimab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Olinvacimab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Olinvacimab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Olinvacimab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Olinvacimab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Olinvacimab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Olinvacimab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Olinvacimab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Olinvacimab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Olinvacimab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Olinvacimab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Olinvacimab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Olinvacimab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Olinvacimab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Olinvacimab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Olinvacimab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Olinvacimab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Olinvacimab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Olinvacimab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Olinvacimab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Olinvacimab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Olinvacimab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Olinvacimab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Olinvacimab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Olinvacimab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Olinvacimab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Olinvacimab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Olinvacimab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Olinvacimab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Olinvacimab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Olinvacimab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Olinvacimab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Olinvacimab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Olinvacimab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Olinvacimab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Olinvacimab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Olinvacimab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Olinvacimab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Olinvacimab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Olinvacimab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Olinvacimab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Olinvacimab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Olinvacimab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Olinvacimab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Olinvacimab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Olinvacimab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Olinvacimab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Olinvacimab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Olinvacimab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Olinvacimab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Olinvacimab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Olinvacimab. |
| Hepatitis B immune globulin | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Olinvacimab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Olinvacimab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Olinvacimab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Olinvacimab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Olinvacimab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Olinvacimab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Olinvacimab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Olinvacimab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Olinvacimab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Olinvacimab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Olinvacimab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Olinvacimab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Olinvacimab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Olinvacimab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Olinvacimab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Olinvacimab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Olinvacimab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Olinvacimab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Olinvacimab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Olinvacimab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Olinvacimab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Olinvacimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Olinvacimab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Olinvacimab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Olinvacimab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Olinvacimab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Olinvacimab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Olinvacimab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Olinvacimab. |